伊曲康唑影响的药代动力学相互作用研究进展

摘要/Abstract

摘要： 伊曲康唑为三唑类广谱抗真菌药, 临床应用广泛, 具有CYP3A4 和P-糖蛋白抑制作用。由于临床CYP3A4 和P-糖蛋白底物广泛, 它们在口服药物吸收的主要部位胃肠道均有高表达, 同时两者的底物具有显著的重叠性, 由此导致的受伊曲康唑影响的药代动力学相互作用广泛产生, 甚至引起显著的临床意义。本文综述并讨论了受其影响的药代动力学相互作用研究, 以促进临床的安全用药。

关键词: 伊曲康唑, 抗真菌药, 药代动力学, 药物相互作用

Abstract: Itraconazole, as one of the broad-spectrum antifungal drugs, is an inhibitor of CYP3A4 and P-glycoprotein and was widely used in clinic.CYP3A4 and P-glycoprotein with extensive substrate have present at high levels in gastrointestinal tract, the primary site of absorption for orally administrated drugs, and share a significant overlap in substrate specificity, thus resulting in widely pharmacokinetic interaction by itraconazole, part of which has clinical importance.In this article, the effect of itraconazole on pharmacokinetic drug-drug interactions is reviewed and discussed in order to promote its safe usage.

Key words: itraconazole, antifugal drug, pharmacokinetics, drug-drug interaction

中图分类号:

R969

苗彩云, 陈漪, 陈江飞. 伊曲康唑影响的药代动力学相互作用研究进展[J]. 中国临床药理学与治疗学, 2009, 14(10): 1183-1192.

MIAO Cai-yun, CHEN Yi, CHEN Jiang-fei. Progress and research in the effect of itraconazole on pharmacokinetic drug-drug interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1183-1192.

参考文献

[1] Isoherranen N, Kunze KL, Allen KE, et al.Role of itraconazole metabolites in CYP3A4 inhibition[J].Drug Metab Dispos, 2004, 32(10):1121-1131.
[2] Templeton IE, Thummel KE, Kharasch ED, et al.Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo[J].Clin Pharmacol Ther, 2008, 83(1):77-85.
[3] Neuvonen PJ, Jalava KM.Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid[J]. Clin Pharmacol Ther, 1996, 60(1):54-61.
[4] Kivisto KT, Kantola T, Neuvonen PJ.Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin[J].Br J Clin Pharmacol, 1998, 46(1):49-53.
[5] Neuvonen PJ, Kantola T, Kivisto KT.Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole[J].Clin Pharmacol Ther, 1998, 63(3):332-341.
[6] Kantola T, Kivisto KT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics of atorvastatin [J].Clin Pharmacol Ther, 1998, 64(11):58-65.
[7] Kantola T, Kivisto KT, Neuvonen PJ.Effect of itraconazole on cerivastatin pharmacokinetics [J].Eur J Clin Pharmacol, 1999, 54(11):851-855.
[8] Cooper KJ, Martin PD, Dane AL, et al.Effect of itraconazole on the pharmacokinetics of rosuvastatin [J].Clin Pharmacol Ther, 2003, 73(4):322-329.
[9] Olkkola KT, Ahonen J, Neuvonen PJ.The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam[J].Anesth Analg, 1996, 82(3):511-516.
[10] Neuvonen PJ, Varhe A, Olkkla KT.The effect of ingestion time interval on the interaction between itraconazole and triazolam[J].Clin Pharmacol Ther, 1996, 60(3):326-331.
[11] Yasui N, KondoT, Otani K, et al.Effect of itraconazole on the sigle oral dose pharmacokinetics and pharmacodynamics of alprazolam[J].Psy chopharmacol, 1998, 139(3):269-273.
[12] Osanai T, Ohkubo T, Yasui N, et al.Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam[J].Br J Clin Pharmacol, 2004, 58(5):476-481.
[13] Araki K, Yasui-Furukori N, Fukasawa T, et al.Inhibition of the metablism of etizolam by itraconazole in humans:evidence for the involvement of CYP3A4 in etizolam metabolism[J].Eur J Clin Pharmacol, 2004, 60(6):427-430.
[14] Kato K, Yasui-Furukori N, Fukasawa T, et al.Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug[J]. Ther Drug Monit, 2003, 25(4):473-477.
[15] Ahonen J, Olkkola KT, Neuvonen PJ.The effect of antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam[J].Fundam Clin Pharmacol, 1996, 10(3):314-318.
[16] Ahonen J, Olkkola KT, Neuvonen PJ.Lack of effect of antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of temazepam[J].Ther Drug Monit, 1996, 18(2):124-127.
[17] Otsuji Y, Okuyama N, Aoshima T, et al.No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam [J].Ther Drug Monit, 2002, 24(3):375-378.
[18] Oda M, Kotegawa T, Tsutsumi K, et al.The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers[J].Eur J Clin Pharmacol, 2003, 59(8 9):615-619.
[19] Luurila H, Kivisto KT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem[J].Eur J Clin Pharmacol, 1998, 54(2):163-166.
[20] Varis T, Kivisto KT, Backman JT, et al.The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal- suppressant effect [J].Clin Pharmacol Ther, 2000, 68(5):487-494.
[21] Lebrun-Vignes B, Archer VC, Diguet B, et al.Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects[J].Br J Clin Pharmacol, 2001, 51(5):443-450.
[22] Varis T, Kivisto KT, Backman JT, et al.Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers[J].Pharmacol Toxicol, 1999, 85(1):29-32.
[23] Raaska K, Niemi M, Neuvonen M, et al.Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole [J].Clin Pharmacol Ther, 2002, 72(4):362-369.
[24] Leather H, Boyette RM, Tian L, et al.Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant re-Chin J Clin Pharmacol Ther 2009 Oct;14(10) cipients[J].Biol Blood Marrow Transplant, 2006, 12(3): 325-334.
[25] Florea NR, Capitano B, Nightingale CH, et al.Beneficial pharmacokinetics interaction between cyclosporine and itraconazole in renal transplant recipients[J].Transplant Proc, 2003, 35(8):2873-2877.
[26] Isohanni MH, Neuvonen PJ, Palkama VJ, et al.Effect of erythromy cin and itraconazole on the pharmacokinetics of intravenous lignocaine[J].Eur J Clin Pharmacol, 1998, 54(7):561-565.
[27] Isohanni MH,Neuvonen PJ, Olkkola KT.Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine[J].27] Isohanni MH,Neuvonen PJ, Olkkola KT.Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine[J].Pharmacol Toxicol, 1999, 84(3):143-146.
[28] Isohanni MH, Neuvonen PJ, Olkkola KT.Effect of itraconazole on the pharmacokinetics of inhaled lidocaine[J].28] Isohanni MH, Neuvonen PJ, Olkkola KT.Effect of itraconazole on the pharmacokinetics of inhaled lidocaine[J].Basic Clin Pharmacol Toxicol, 2004, 95(3):120-123.
[29] Palkama VJ, Neuvonen PJ, Olkkola KT.Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in heathy volunteers[J].29] Palkama VJ, Neuvonen PJ, Olkkola KT.Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in heathy volunteers[J].Br J Anaesth, 1999, 83(4):659-661.
[30] Jokinen MJ, Ahonen J, Neuvonen PJ, et al.Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine[J].Pharmacol Toxicol, 2001, 88(4):187-191.
[31] Nieme M, Backman JT,Neuvonen M, et al.Effects of gemfibrozil, itraconazole and their combination on the pharmacokinetics and pharmacodynamics of repaglinide:potentially hazardous interaction between gemfibrozil and repaglinide[J].Diabetologia, 2003, 46(3):347-351.
[32] Niemi M, Tornio A, PasanenMK, et al.Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide[J].Eur J Clin Pharmacol, 2006, 62(6):463-472.
[33] Niemi M, Backman JT, Juntti-Patinen L, et al.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide[J].Br J Clin Pharmacol, 2005, 60(2):208-217.
[34] Jaakkola T, Backman JT, Neuvonen M, et al.Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone[J].Clin Pharmacol Ther, 2005, 77(5):404-414.
[35] Jalava KM, Olkkola KT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone[J].35] Jalava KM, Olkkola KT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone[J].Eur J Clin Pharmacol, 1996, 51(3 4):331-334.
[36] Kivisto KT, Lamberg TS, Kantola T, et al.Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole[J].Clin Pharmacol Ther, 1998, 62(3):348-354.
[37] Raaska K, Neuvonen PJ.Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole[J].37] Raaska K, Neuvonen PJ.Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole[J].Eur J Clin Pharmacol, 1998, 54(2):167-170.
[38] Park JY, Shon JH, Kim KA, et al.Combined effects of itraconazole and CYP2D6^* 10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects[J].J Clin Psychopharmacol, 2006, 26(2):135-142.
[39] Kubo M, Koue T, Inaba A, et al.Influence of itraconazole co-administration and CYP2D6 Genotype on the pharmacokinetics of the new antipsychotic aripiprazole [J].Drug Metab Pharmacokinet, 2005, 20(1):55-64.
[40] Jung SM, Kim KA, Cho HK, et al.Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients [J].Clin Pharmacol Ther, 2005, 78(5):520-528.
[41] Masui T, Kusumi I, Takahashi Y, et al.Effect of itraconazole and tandospirone on the pharmacokinetics of perospirone[J].Ther Drug Monit, 2006, 28(1):73-75.
[42] Jalava KM, Olkkola KT, Neuvonen PJ.Itraconazole greatly increases plasma concentrations and effects of felodipine [J].42] Jalava KM, Olkkola KT, Neuvonen PJ.Itraconazole greatly increases plasma concentrations and effects of felodipine [J].Clin Pharmacol Ther, 1997, 61(4):410-415.
[43] Damkier P, Hansen LL, Brosen K.Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromy cin on the pharmacokinetics of quinidine[J].43] Damkier P, Hansen LL, Brosen K.Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromy cin on the pharmacokinetics of quinidine[J].Br J Clin Pharmacol, 1999, 48(6):829-838.
[44] Kaukonen KM, Olkkola KT, Neuvonen PJ.Itraconazole increases plasma concentrations of quinidine[J].44] Kaukonen KM, Olkkola KT, Neuvonen PJ.Itraconazole increases plasma concentrations of quinidine[J].Clin Pharmacol Ther, 1997, 62(5):510-517.
[45] Stass H, Nagelschitz J, Moeller JG, et al.Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200mg oral itraconazole given once a day in healthy subjects[J].Int J Clin Parmacol Ther, 2004, 42(1):23-29.
[46] Shi J, Montay G, Leroy B, et al.Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromy cin [J].Pharmacotherapy, 2005, 25(1):42-51.
[47] Jaruratanasirikul S, Sriwiriyajan S.Pharmacokinetic study of the interaction between itraconazole and nevirapine[J].47] Jaruratanasirikul S, Sriwiriyajan S.Pharmacokinetic study of the interaction between itraconazole and nevirapine[J]. Eur J Clin Pharacol, 2007, 63(5):451-456.
[48] Lefebvre RA, Van Peer A, Woestenborghs R.Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole [J].48] Lefebvre RA, Van Peer A, Woestenborghs R.Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole [J].Br J Clin Pharmacol, 1997, 43(3):319-322.
[49] Palkama VJ, Neuvonen PJ, Olkkola KT.The CYP 3A4 inhibitor itraconazole has no effedt on the pharmacokinetics of i.v.fentanyl[J].49] Palkama VJ, Neuvonen PJ, Olkkola KT.The CYP 3A4 inhibitor itraconazole has no effedt on the pharmacokinetics of i.v.fentanyl[J].Br J Anaesth, 1998, 81(4):598-600.
[50] Kivisto KT, Wang JS, Backman JT, et al.Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole[J].Eur J Clin Pharmacol, 2001, 57(1):37-42.
[51] Swaisland HC, RansonM, Smith RP, et al.Pharmacokinetic drug interaction of Gefitinib with rifampicin, itraconazole and metoprolol[J].Clin Pharmacokinet, 2005, 44(10): 1067-1081.
[52] Hynninen VV, Olkkola KT, Bertilsson L, et al.Voriconazole increases while itraconazole decreases plasma meloxicam concentrations[J].Antimicrob Agent Chemother, 2009, 53(2):587-592.
[53] Wang E, Lew K, Casciano CN, et al.Interaction of common azole antifungals with Pglycoprotein[J].Antimicrob Agent Chemother, 2002, 46(1):160-165.
[54] Shimizu M, Uno T, Sugawara K, et al.Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein[J].Br J Clin Pharmacol, 2006, 61(5):538-544.
[55] ShimizuM, Uno T, Sugawara K, et al.Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein[J].Br J Clin Pharmacol, 2006, 62(3):372-376.
[56] Uno T, Shimizu M, Sugawara K, et al.Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine[J].Drug Metab Dispos, 2006, 34(11):1875-1879.
[57] Partanen J, Jalava KM, Neuvonen PJ.Itraconazole increases serum digoxin concentration [J].57] Partanen J, Jalava KM, Neuvonen PJ.Itraconazole increases serum digoxin concentration [J].Pharmacol Toxicol, 1996, 79(5):274-276.
[58] Jalava KM, Partanen J, Neuvonen PJ.Itraconazole decreases renal clearance of digoxin[J].58] Jalava KM, Partanen J, Neuvonen PJ.Itraconazole decreases renal clearance of digoxin[J].Ther Drug Monti, 1997, 19(6):609-613.
[59] Karyekar CS, Eddington ND, Briglia A, et al.Renal interaction between itraconazole and cimetidine [J].J Clin Pharmacol, 2004, 44(8):919-927.
[60] Takara K, Tanigawara Y, Komada F, et al.Cellular pharmacokinetic aspects of reversal effect of itraconazole on Pglycoprotein- mediated resistance of anticancer drugs[J]. Biol Pharm Bull, 1999, 22(12):1355-1359.
[61] Lilja JJ, Backman JT, Laitila J, et al.Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol[J].Clin Pharmacol Ther, 2003, 73(3):192-198.
[62] Lilja JJ, Backman JT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics of atenolol[J].62] Lilja JJ, Backman JT, Neuvonen PJ.Effect of itraconazole on the pharmacokinetics of atenolol[J].Basic Clin Pharmacol Toxicol, 2005, 97(6):395-398.
[63] Yasui-Furukori N, Saito M, Niioka T, et al.Effect of itraconazole on pharmacokinetics of paroxetine:the role of gut transporters[J].Ther Drug Monit, 2007, 29(1):45-48.
[64] Heiskanen T, Backman JT, Neuvonen M, et al.Itraconazole, a potent inhibitor of P-gly coprotein, moderately increases plasma concentrations of oral morphine[J].Acta Anaesthesiol Scand, 2008, 52(10):1319-1326.